This phase III trial is trying to determine the overall survival of patients with hepatocellular (liver) cancer who receive two types of immunotherapy (nivolumab plus ipilimumab) versus those who receive standard care (targeted therapy with sorafenib or lenvatinib).
This trial is treating patients with hepatocellular (liver) cancer.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma
Bristol-Myers Squibb (BMS)
Eligible patients will be randomised to receive the experimental (Nivolumab + Ipilimumab) or comparative treatment (Sorafenib or lenvatinib).
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More